James D. Cooper, MD, MSc
- Associate Professor of Pediatrics
Administrative Assistant: Ashley Kosarich
Dr. Cooper acts as the clinical director of coagulation disorders within the Division of Pediatric Hematology/Oncology. The coagulation clinic cares for a large number of children with bleeding disorders and thrombosis concerns. As part of that mission, Dr. Cooper and Dr. Tahniat Syed of Adolescent Medicine co-lead a dedicated clinic for young women with menstrual disorders, known as the CHAMP (Comprehensive Hematologic Assessment of Adolescents with Menstrual Problems) Clinic. In addition to coagulation disorders, Dr. Cooper also cares for children with a variety of oncologic and other hematologic problems.
Professional and Scientific Society Memberships
- American Society of Pediatric Hematology and Oncology, 2006-Present
- American Society of Hematology, 2006-Present
- Children’s Oncology Group, 2009-Present
- Critical Mass Young Adult Alliance, 2010-Present
- American Thrombosis & Hemostasis Network, 2011-Present
- American Academy of Pediatrics, 2015-Present
- Foundation for Women and Girls with Bleeding Disorders, 2015-Present
- Hemostasis and Thrombosis Research Society, 2018-Present
Education & Training
- BA, Anthropology and Pre-Professional Studies, University of Notre Dame, 1999
- MD, University of Connecticut, 2003
- Residency and Internship in Pediatrics, University of Connecticut-Connecticut Children's Medical Center, 2003-2006
- Fellow in Pediatric Hematology-Oncology, UPMC Children's Hospital of Pittsburgh, 2006-2009
- MSc, Clinical Research, University of Pittsburgh Institute for Clinical Research Education, 2009
Malec LM, Sidonio RF, Smith KJ, & Cooper JD. Three cost-utility analyses of screening for intracranial hemorrhage in neonates with hemophilia. J Pediatr Hematol Oncol. 2014 Aug; 36(6):474-9. PubMed PMID: 25054457.
Boiko JR, Srinath AI, & Cooper JD. Portomesenteric venous thrombosis in previously healthy adolescents presenting with subacute abdominal pain. Clin Pediatr (Phila). 2016 Sep; 55(10):975-8. PubMed PMID: 26581354.
Cooper JD & Ritchey AK. Response to treatment and adverse events associated with use of recombinant activated factor VII in children: a retrospective cohort study. Ther Adv Drug Saf. 2016 Oct 20; 8(2):51-59. PubMed PMID: 28255432.
Cooper JD, Costello AG, & Shaw PH. A comparison of extremity thrombosis rates in adolescent and young adult (AYA) versus younger pediatric oncology patients at a children’s hospital. J Adolesc Young Adult Oncol. 2017 Mar; 6(1):62-66. PubMed PMID: 27779446.
Woiewodski L, Ezon D, Cooper J, Feingold B. Barth syndrome with late-onset cardiomyopathy: a missed opportunity for diagnosis. J Pediatr. 2017 Apr; 183:196-198. PubMed PMID: 28108107.
Woiewodski L, Ezon D, Cooper J, Feingold B. Reply to: Acquired noncompaction in Barth syndrome due to the TAZ mutation c.481_482ins20. J Pediatr. 2017 Jul; 186:214-15. PubMed PMID: 28336143.
Leeper CM, Vissa M, Cooper JD, Malec LM, Gaines BA. Venous thromboembolism in pediatric trauma patients: ten-year experience and long-term follow-up in a tertiary care center. Pediatr Blood Cancer. 2017 Aug; 64(8). PubMed PMID: 28067012.
Geramita MA, Hofer, J, Cooper J, Moritz ML. Decreased severity of Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS) in a child with type 1 von Willebrand disease. BMJ Case Rep. 2017 Aug 30. ePub ahead of print. PubMed PMID: 28855217.
Malec LM, Cooper J, Rudolph J, Michaels MG, Ragni MV. Prophylactic rtPA in the prevention of line-associated thrombosis and infection in short bowel syndrome. J Pediatr Gastroenterol Nutr. 2017 Nov 10. ePub ahead of print. PubMed PMID: 29135819.
Stanley K & Cooper J. Hormone therapy and venous thromboembolism in a transgender adolescent. J Pediatr Hematol Oncol. 2018 Jan; 40(1):e38-e40. PubMed PMID: 28945660.
McCormick MC, Siripong N, & Cooper JD. Desmopressin stimulation testing: response to intravenous and intranasal forms. Haemophilia. 2018 Mar 26. ePub ahead of print. PubMed PMID: 29578274.
Academic and Research Interests
All Children's Hospital, Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children (the Kids-DOTT Trial) (Local PI, 2% effort), 2015-Present, $700.
Pediatric Orthopaedic Society of North America, Coagulation analysis of patients undergoing spine surgery receiving tranexamic acid (Co-I, 1% effort), 2016-Present, $50,000.
Boehringer Ingelheim, Open-label, randomized, parallel-group, active-controlled, multi-centre, non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birth to less than 18 years of age (the DIVERSITY study) (Local PI, 1% effort), 2017-Present.
Boehringer Ingelheim, Open-label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years (Local PI, 1% effort), 2017-Present.